Editor’s note

Pharma companies should not be the ones held responsible for the high prices of medicines

The CBI has reportedly found cases with the same modus operandi: failing batches and then approving them for a price

The second patent cliff is around the corner, as patents for branded molecules with cumulative global sales of over $ 251 billion…

The RCEP negotiation is one of the BJP-led NDA-2 government’s first challenges as it links directly to the stated goal to make…

Delayed implementation of the API policy has resulted in India’s dependence on China

With actual fiscal outcomes for FY19 falling short of the revenue estimates put out in the interim budget, FM Sitharaman will have…

Will US President Trump’s mission to Make America Great Again turn out to be a great fillip for PM Modi’s Make in India campaign?…

Rather than living in denial and shooting the messenger (Eban in this case), pharma companies have to own up to their mistakes,…

While both governments continue the dialogue, there are various groups working to find a middle path

Will we be safeguarding our national health priorities and standards if we toe the USTR’s line or get a better rank on the GIPC IP…